VirtualScopics, Inc. Reports 2015 Third Quarter Revenues Increase 18% From Prior Year Period And Company Achieves Positive Adjusted EBITDA

ROCHESTER, N.Y., Oct. 29, 2015 -- VirtualScopics, Inc. (VSCP), a leading provider of clinical trial imaging solutions, today reported financial results for the third quarter and nine months ended September 30, 2015.

Revenues for the third quarter of 2015 increased 18% to $3,224,407 compared to $2,741,241 for the third quarter of 2014. The company reported positive Adjusted EBITDA in the third quarter of 2015 of $132,101 as compared to negative Adjusted EBITDA of $842,772 in the third quarter of 2014. VirtualScopics reported a net loss for the third quarter of 2015 of $24,779, or $0.02 loss per share, representing a 97% improvement from a net loss of $955,523, or $0.33 loss per share, reported in the third quarter of 2014.

Read more: VirtualScopics Inc ( VSCP )

Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders

Combined Product Portfolio to Provide Clinicians With a Broad Range of Endovascular AAA Devices
Will Expand U.S. and European Sales Organizations to Enhance Growth and Provide Excellent Clinical Support
Endologix to Host Conference Call Today at 5:00 p.m. ET

IRVINE, Calif., and SANTA ROSA, Calif., Oct. 26, 2015  -- Endologix, Inc. (ELGX) and TriVascular Technologies, Inc. (TRIV) announced today that they have entered into a definitive merger agreement under which Endologix and TriVascular will combine in a stock and cash transaction. The transaction is valued at $9.10 per TriVascular share, or a total of approximately $211 million, based on Endologix's closing stock price of $13.81 per share on October 23, 2015.

Read more: TriVascular Technologies Inc ( TRIV )

Dehaier Wins Medical Equipment Procurement Bid Financed by China Development Bank

BEIJING, Oct. 19, 2015 -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM) ("Dehaier" or the "Company"), which develops, markets and sells medical devices and wearable sleep respiratory products in China, today announced that it has won a medical device distribution bid for a new rural healthcare construction project supported by China Development Bank Corp ("CDB"). According to the agreement, Dehaier will provide its proprietary C-arm X-Ray machine and defibrillator monitor to Dongsheng Hospital of Ordos, Inner Mongolia. The procurement project is funded by CDB, one of China's three national policy banks.

Read more: Dehaier Medical Systems Ltd ( DHRM )

Spectranetics Achieves Third Quarter 2015 Revenue of $61.7 Million

COLORADO SPRINGS, Colo., Oct. 22, 2015 -- The Spectranetics Corporation (SPNC) today reported financial results for the three and nine months ended September 30, 2015. Highlights of the quarter, all compared with the three months ended September 30, 2014 include:

  • Revenue of $61.7 million increased 5% (7% constant currency1)
  • Vascular Intervention revenue of $40.4 million increased 10% (12% constant currency)
  • Lead Management revenue of $18.0 million increased 2% (5% constant currency)

"We are pleased with our third quarter results, marked by solid performance within our Vascular Intervention, Lead Management and International businesses. We believe that our team, portfolio, product pipeline and clinical data position us to capitalize on the compelling growth opportunities ahead," said Scott Drake, President and Chief Executive Officer.

Read more: The Spectranetics Corporation ( SPNC )

Intersect ENT Announces FDA Submission to Seek Expanded Indication of PROPEL Mini Steroid Releasing Implant to Treat Patients With Frontal Sinus Disease

MENLO PARK, Calif.-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the company has submitted a supplemental premarket approval (PMA-s) submission to the U.S. Food and Drug Administration (FDA) to seek approval to expand the indication of the PROPEL® mini steroid releasing sinus implant to the treatment of patients undergoing frontal sinus surgery.

An expanded indication would allow Intersect ENT to market placement of PROPEL mini in the frontal sinuses, which are located behind the eyebrows. PROPEL mini is currently indicated for placement in the ethmoid sinuses, located just behind the bridge of the nose.

Read more: Intersect ENT Inc ( XENT )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker